Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Mental health problems in children and adolescents contributed to a global prevalence of 13% in 2015. In 2019, about one in seven of the world's 10–19 year olds experienced a mental health disorder, a total of about 165 million young people. Adolescence is a critical and unique phase of development in psychological growth. Children having mental health problems can have adverse outcomes, such as poor school performance, social difficulties, substance abuse, and poor physical health. The adverse effects even extend beyond the children themselves - increased reliance on public sector services and healthcare services, loss productivity among parents or care-givers, and burden to society. More than half of mental health conditions start before a child reaches 20 years of age, with onset occurring in adolescence much more frequently than it does in early childhood or adulthood. However, pre-school children with early mental health problems are increasing in prevalence in the 21st century. Many such cases go undetected and untreated. In the United States, in 2021, at least roughly 17.5% of the population (ages 18 and older) were recorded as having a mental illness. The comparison between reports and statistics of mental health issues in newer generations (18–25 years old to 26–49 years old) and the older generation (50 years or older) signifies an increase in mental health issues as only 15% of the older generation reported a mental health issue whereas the newer generations reported 33.7% (18–25) and 28.1% (26–49).
Cryofibrinogenemia is an acquired disorder in which fibrinogen precipitates at cold temperatures and may lead to the intravascular precipitation of fibrinogen, fibrin, and other circulating proteins, thereby causing the infarction of various tissues and bodily extremities. Cryoglobulinemia may occur without evidence of an underlying associated disorder, i.e. primary cryoglobulinemia (also termed essential cryoglobulinemia) or, far more commonly, with evidence of an underlying disease, i.e. secondary cryoglobulinemia. Secondary cryofibrinogenemia can develop in individuals with infection (c. 12% of cases), malignant or premalignant disorders (21%), vasculitis (25%), and autoimmune diseases (42%). In these cases, cryofibrinogenemia may or may not cause tissue injury and/or other symptoms and the actual cause-effect relationship between these diseases and the development of cryofibrinogenemia is unclear. Cryofibrinogenemia can also occur in association with the intake of certain drugs.
== Material advances == Recent advances in out of autoclave (OOA) processes hold promise for improving performance and lowering costs for composite structures. Using vacuum-bag-only (VBO) for atmospheric pressures, the new OOA processes promise to deliver less than 1 percent void content required for aerospace primary structures. Led by material scientists at Air Force Research Lab, the technique would save the costs of constructing and installing large structure autoclaves ($100M saved at NASA) and making small production runs of 100 aircraft economically viable.
Organized crime groups also do a range of business and labor racketeering activities, such as skimming casinos, insider trading, setting up monopolies in industries such as garbage collecting, construction and cement pouring, bid rigging, getting "no-show" and "no-work" jobs, political corruption and bullying.
The AST/ALT ratio or De Ritis ratio is the ratio between the concentrations of two enzymes, aspartate transaminase (AST) and alanine transaminase, a.k.a. alanine aminotransferase (ALT), in the blood of a human or animal. It is used as one of several liver function tests, and measured with a blood test. It is sometimes useful in medical diagnosis for elevated transaminases to differentiate between causes of liver damage, or hepatotoxicity. Most causes of liver cell injury are associated with a greater increase in ALT than AST, but an AST/ALT ratio of 2:1 or greater is suggestive of alcoholic liver disease, particularly in the setting of an elevated gamma-glutamyl transferase. The AST/ALT ratio can also occasionally be elevated in a liver disease pattern in patients with nonalcoholic steatohepatitis, and it is frequently elevated in an alcoholic liver disease pattern in patients with hepatitis C who have developed cirrhosis. In addition, patients with Wilson's disease or cirrhosis due to viral hepatitis may have an AST that is greater than the ALT, though the ratio typically is not greater than two. When the AST is higher than ALT, a muscle source of these enzymes should be considered. For example, muscle inflammation due to dermatomyositis may cause AST > ALT. This is a good reminder that AST and ALT are not good measures of liver function when other sources may influence AST and/or ALT, because they do not reliably reflect the synthesizing ability of the liver, and they may come from tissues other than liver (such as muscle).
Sources: en.wikipedia.org
In protein design, the target structure (or structures) of the protein are known. However, a rational protein design approach must model some flexibility on the target structure in order to increase the number of sequences that can be designed for that structure and to minimize the chance of a sequence folding to a different structure. For example, in a protein redesign of one small amino acid (such as alanine) in the tightly packed core of a protein, very few mutants would be predicted by a rational design approach to fold to the target structure, if the surrounding side-chains are not allowed to be repacked. Thus, an essential parameter of any design process is the amount of flexibility allowed for both the side-chains and the backbone. In the simplest models, the protein backbone is kept rigid while some of the protein side-chains are allowed to change conformations. However, side-chains can have many degrees of freedom in their bond lengths, bond angles, and χ dihedral angles. To simplify this space, protein design methods use rotamer libraries that assume ideal values for bond lengths and bond angles, while restricting χ dihedral angles to a few frequently observed low-energy conformations termed rotamers. Rotamer libraries are derived from the statistical analysis of many protein structures. Backbone-independent rotamer libraries describe all rotamers. Backbone-dependent rotamer libraries, in contrast, describe the rotamers as how likely they are to appear depending on the protein backbone arrangement around the side chain.
=== Misuse potential === Baclofen can produce a feeling of well-being, relaxation, and mild euphoria. Baclofen, at standard dosing, does not appear to possess addictive properties, and has not been associated with any degree of drug craving.
Following the 1494 Treaty of Tordesillas, the land now called Brazil was claimed for the Portuguese Empire on 22 April 1500, with the arrival of the Portuguese fleet commanded by Pedro Álvares Cabral. Along the coast, the Portuguese encountered various Indigenous communities, most of whom spoke languages of the Tupi–Guarani family. Though the first settlement, São Vicente, was founded in 1532, colonization effectively began in 1534, when King John III of Portugal divided the territory into the fifteen private and autonomous captaincies. However, the decentralized and unorganized captaincy system proved unsuccessful, and in 1549 the Portuguese king restructured them into the Governorate General of Brazil in the city of Salvador, which became the capital of a single and centralized Portuguese colony in South America. In the first two centuries of colonization, Indigenous and European groups lived in constant war, establishing opportunistic alliances in order to gain advantages against each other.
Humans cannot catch warts from toads or other animals; the bumps on a toad are not warts. Warts on human skin are caused by human papillomavirus, which is known to affect only humans. Cracking one's knuckles does not cause osteoarthritis. In people with eczema, bathing does not dry the skin as long as a moisturizer is applied soon after. If moisturizer is not applied after bathing, then the evaporation of water from the skin can result in dryness. There have never been any programs in the US that provide access to dialysis machines in exchange for pull tabs on beverage cans. This rumor has existed since at least the 1970s, and usually cites the National Kidney Foundation as the organization offering the program. The Foundation itself has denied the rumor, noting that dialysis machines are primarily funded by Medicare. Rhinoceros horn in powdered form is not used as an aphrodisiac in traditional Chinese medicine as Cornu Rhinoceri Asiatici (犀角, xījiǎo, "rhinoceros horn"). It is prescribed for fevers and convulsions, a treatment not supported by evidence-based medicine. Leprosy is not auto-degenerative as commonly supposed, meaning that it will not (on its own) cause body parts to be damaged or fall off. Leprosy causes rashes to form and may degrade cartilage and, if untreated, inflame tissue. In addition, leprosy is only mildly contagious, partly because 95% of those infected with the mycobacteria that cause leprosy do not develop the disease.
== Natural occurrence == Previously thought to be an exclusively synthetic compound, it has been reported to occur naturally in Argyreia nervosa (Hawaiian baby woodrose). The drug is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
In March 2001 the license for Trovan was withdrawn in Europe, by the European Commission due to liver toxicity and some deaths. In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed. In December 2010, the United States diplomatic cables leak indicated that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general Michael Aondoakaa to persuade him to drop legal action. The Washington Post reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail". In response, the company released a press statement describing the allegations as "preposterous" and saying that it acted in good faith. Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case, was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010. The lawsuits were eventually settled out of court. Pfizer committed to paying US$35 million "to compensate the families of children in the study", another $30 million to "support healthcare initiatives in Kano", and $10 million to cover legal costs. Payouts began in 2011.
Lt. Col. J. H. Fuller (18 April 1909 – 1 April 1911) Maj. Gordon Vallancy Drury (1 April 1911 – 28 January 1913) Maj. Gen. Sir Alfred Hamilton Mackenzie Edwards (28 January 1913 – 23 January 1923) Col. Algernon Essex Capell (1 February 1923 – 11 February 1926) Alfred James Tomlinson (12 February 1926 – 12 May 1926; acting) Col. George Stops (13 May 1926 – 14 February 1933) Brig. John Sidney Morris (15 February 1933 – 24 April 1945) Brig. John Ellis "Jack" Ross (24 April 1945 – 6 December 1950) Col. James Appleby (7 December 1950 – 2 June 1954) Col. Arthur Selwyn Hickman (3 June 1954 – 5 November 1955) Col. Harold Jackson (6 November 1955 – 12 March 1958) Basil Gordon Spurling (13 March 1958 – 25 April 1963) Frank Eric Barfoot (26 April 1963 – 2 January 1968) James Spink (3 January 1968 – 26 June 1970) Sydney Frederick Samuel Bristow (27 June 1970 – 6 February 1974) Peter Dennis Wray Richard Sherren (7 February 1974 – 6 February 1978) Peter Kevin Allum (7 February 1978 – 6 February 1982)
== Election process == The president is not directly elected by Burmese voters; instead, they are indirectly elected by the Presidential Electoral College (သမ္မတရွေးချယ်တင်မြှောက်ရေးအဖွဲ့), an electoral body made of three separate committees. One committee is composed of MPs who represent the proportions of MPs elected from each Region or State; another is composed of MPs who represent the proportions of MPs elected from each township population; the third is of military-appointed MPs personally nominated by the Defence Services' commander-in-chief. Each of the three committees nominates a presidential candidate. Afterward, all the Pyidaungsu Hluttaw MPs vote for one of three candidates—the candidate with the highest number of votes is elected president, while the other two are elected as vice-presidents. The president serves for a term of 5 years. Should a president resign for any reason or die in office, the Presidential Electoral College will meet and each of the three committees will nominate a candidate to finish out the prior President's term so that the terms of the legislature and presidency are synchronised. The candidate who receives the most votes from the nominees is elected. This process is similar to the one prescribed by the 1947 Constitution, in which MPs from the Parliament's Chamber of Nationalities and Chamber of Deputies elected the president by secret ballot. The President was then responsible for appointing a prime minister (on the advice of the Chamber of Deputies), who was constitutionally recognised as the head of government and led the Cabinet.
About 75% of human disease-causing genes have a functional equivalent in the fruit fly genome Its care and culture require little equipment, space, and expense even when using large cultures. It can be safely and readily anesthetized (usually with ether, carbon dioxide gas, by cooling, or with products such as FlyNap). Its morphology is easy to identify once anesthetized. It has a short generation time (about 10 days at room temperature), so several generations can be studied within a few weeks. It has a high fecundity (females lay up to 100 eggs per day, and perhaps 2,000 in a lifetime). Males and females are readily distinguished, and virgin females can be easily identified by their light-colored, translucent abdomen, facilitating genetic crossing. The mature larva has giant chromosomes in the salivary glands called polytene chromosomes, "puffs", which indicate regions of transcription, hence gene activity. The under-replication of rDNA occurs resulting in only 20% of DNA compared to the brain. Compare to the 47%, less rDNA in Sarcophaga barbata ovaries. It has only four pairs of chromosomes—three autosomes, and one pair of sex chromosomes. Males do not show meiotic recombination, facilitating genetic studies. Recessive lethal "balancer chromosomes" carrying visible genetic markers can be used to keep stocks of lethal alleles in a heterozygous state without recombination due to multiple inversions in the balancer. The development of this organism—from fertilized egg to mature adult—is well understood. Genetic transformation techniques have been available since 1987.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.